![]() If these tests are deemed to be part of the treatment plan, then pharmacists will need to be equipped to use this information to ensure hospitals or health systems are adhering to medication-related, evidence-based practice guidelines.ī24k: Identify problem-prone and high-risk therapies using preestablished criteria. Pharmacogenomic markers are currently part of dose adjustment strategies for a variety of drugs.ī23q: Pharmacist expertise in literature evaluation.īeing able to interpret clinical trials evaluating pharmacogenomics-guided treatment will be essential for pharmacists to make decisions on the clinical utility of these markers.ī24g: Play a critical role in ensuring that the hospital or health system adheres to medication-related, evidence-based practice guidelines. Pharmacogenomic laboratory tests are sure to be included in those essential tests which pharmacists should have the authority to order and interpret.ī23i: Authority to adjust dosage for selected medications. If pharmacists are to be able to use patient-specific data to be leaders in disease prevention and wellness, then clearly they will need to be knowledgable of known genetic drivers of disease and medication response in order to identify higher risk patient populations.ī23h: Authority to order serum medication concentrations and other clinically important laboratory analyses. 3 Upon closer inspection of these goals, one can see the powerful potential of emerging genomics knowledge on patient care and that pharmacists are perfectly positioned to lead this aspect of precision medicine.ī21: Pharmacists should use patient-specific data to be leaders in disease prevention and wellness. Although this is the only goal explicitly stating that genetics has a clear role in the delivery of care, one can easily extend this to several other goals where the use of this science is essential in providing advanced care (B21, B23h, B23i, B23q, B24g, B24k, B26, C13, and C14) ( Table 1). Included in the PPMI recommendation is a statement for optimal pharmacy practice model that pharmacists should be able to make adjustments of medication regimens based on genetic characteristics of the patient (B23f). 3 Ten recommendations were reviewed and included by the Emerging Sciences Section Advisory Group goals for implementation of pharmacogenomics in hospitals and health systems for optimal patient care. If the profession of pharmacy is to accomplish the goal of the PPMI by developing futuristic pharmacy practice models, then the science of pharmacogenomics will need to be incorporated into patient care.Ī list of 147 points of consensus for optimal pharmacy practice was created in 2011 at the ASHP Pharmacy Practice Model Summit. 2 An increasing number of newly approved medications include genomic biomarkers in the drug labeling which can help predict response, and research continues to identify predictive genomic markers for existing medications. Pharmacogenomics is defined as the study of how genes affect a patient’s response to medications. Among these, pharmacogenomics has been in the spotlight as a means of personalizing medicine to identify the most effective medications and to avoid those of potential harm for individual patients. Examples include pharmacogenomics, gene therapy, biosimilars, and nanotechnology. 1 In order to fulfill this goal, pharmacists will need to make use of current and emerging technologies and science to lead initiatives impacting medication management and delivery.Įmerging sciences currently impacts medication management and delivery. ![]() A Pharmacy Practice Model Summit was convened in 2011, and the goal of the PPMI was to significantly advance patient health and well-being by developing and disseminating a futuristic practice model that supports the most effective use of pharmacists as direct patient care providers. In a bold effort to engage key stakeholders to create forward-thinking hospital and health-system practices, the American Society of Health-System Pharmacists (ASHP) and the ASHP Research and Education Foundation initiated the Pharmacy Practice Model Initiative (PPMI) and its successor the Practice Advancement Initiative (PAI). The profession of pharmacy is at a critical juncture where there is an urgent need to maintain the level of practice ahead of the ever-changing landscape of health care delivery. Institutions described herein can be viewed as a point of contact for those who want to learn more about how these initiatives were developed.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |